White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States.
Show more
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and acute care hospitals offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
HCA Healthcare, Inc (H1CA34) currently trades at R$111.66, while our model-based Fair Value estimate is R$123.09, implying the stock looks roughly 9.3% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of R$175.67 per share, and 16 of the 23 models we run sit above the R$111.66 price.
Bear case: the Dividend Discount group reads lowest at R$12.62, and 7 of the 23 models stay below the price. Evidence for this calculation is high.
Scenario range: R$59.07 (bear) to R$190.84 (bull), the price of R$111.66 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
HCA Healthcare, Inc reported revenue of $75.6B in FY2025 versus $60.2B in FY2022, a compound +7.9%/yr. Reported net income was $6.8B in FY2025, compounding +6.3%/yr from FY2022.
Key figures
Market cap R$422B (≈ $80.8B) · P/E ratio 14.8 · P/S ratio 1.33 · EPS (TTM) R$7.52 · Dividend yield 2.6% · Net margin 9.0% · Return on equity 136% · Return on assets (EBIT) 17.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 10%, H1CA34 screens cheaper than that median.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$3.46 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
R$82.42
R$160.02
R$281.31
74
Growth DCF
R$84.08
R$151.70
R$250.29
73
EPV
R$58.95
R$76.61
R$92.06
71
All 23 models by family
DCF Models
FCF DCF
R$82.42
R$160.02
R$281.31
74
Owner Earnings
R$50.58
R$109.09
R$200.55
69
5Y Revenue Exit
R$78.17
R$157.02
R$258.64
67
5Y EBITDA Exit
R$109.99
R$217.62
R$344.93
70
5Y P/E Exit
R$74.90
R$150.80
R$231.32
66
10Y Revenue Exit
R$74.49
R$147.44
R$247.62
62
10Y EBITDA Exit
R$98.91
R$189.92
R$314.58
63
10Y P/E Exit
R$76.38
R$143.08
R$226.41
60
Earnings-Based
Graham-Dodd
R$54.30
R$183.79
R$246.40
62
Lynch FV
R$42.03
R$60.05
R$78.06
58
PEG = 1.0
R$42.03
R$60.05
R$78.06
55
EPV
R$58.95
R$76.61
R$92.06
71
Dividend Discount
Gordon GGM
R$7.34
R$15.26
R$24.20
63
DDM Multi-Stage
R$7.34
R$12.62
R$16.01
64
Multiples
P/E Multiple
R$131.75
R$175.67
R$219.59
63
P/S Multiple
R$101.81
R$135.75
R$169.68
58
EV/EBIT
R$132.55
R$192.41
R$252.26
65
EV/EBITDA
R$144.41
R$208.21
R$272.02
67
EV/Revenue
R$81.15
R$136.07
R$191.00
52
Growth DCF
Growth DCF
R$84.08
R$151.70
R$250.29
73
Rev-Margin DCF
R$78.17
R$156.68
R$248.96
67
Economic Profit
ROIC Compounder
R$67.14
R$96.94
R$130.98
68
Growth Earnings
Growth-Adj P/E
R$111.64
R$159.48
R$207.32
65
Open the full fair value analysis →
Overall quality
72/100
Of which business quality 68
· Market factors (momentum, volatility) 43
Profitability
77
Margins and returns on capital today
Quality Growth
59
Are margins and returns improving?
Cashflow
62
Earnings quality: real cash, not paper profit
Fin. Strength
48
Balance sheet, leverage, solvency risk
Investment
75
Disciplined investing over empire-building
Low Volatility
49
Calm price path (market factor)
Momentum
42
Price trend over the last 3–12 months (market factor)
52W Momentum
39
Distance to the 52-week high (market factor)
Net Issuance
100
Share count: buybacks or dilution?
Open the full quality analysis →
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.
Pick a strategy and jump into the live analysis with that exact screen applied.
Is HCA Healthcare, Inc (H1CA34) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of R$123.09 versus a price of R$111.66, about +10% upside (undervalued).
What is the fair value of H1CA34?
Our model-based fair value for HCA Healthcare, Inc is R$123.09 (as of Sep 29, 2026), built from audited fundamentals. The current price: R$111.66.
What is the quality score of H1CA34?
HCA Healthcare, Inc has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HCA Healthcare, Inc (H1CA34)?
Our model-based price target is the fair value of R$123.09 (as of Sep 29, 2026) from 23 valuation models. Cautious scenario R$59.07, optimistic scenario R$190.84. It is a calculation from audited fundamentals, not an analyst target.
What is the HCA Healthcare, Inc stock forecast for 2026?
Our models put fair value at R$123.09, about +10% upside versus a price of R$111.66 (undervalued). Cautious scenario R$59.07, optimistic scenario R$190.84. The calculation is refreshed regularly with new filings.
What is the revenue of HCA Healthcare, Inc (H1CA34)?
HCA Healthcare, Inc reported trailing-twelve-month revenue of about $76.4B (latest available figure, as of Sep 29, 2026).
Does HCA Healthcare, Inc pay a dividend?
HCA Healthcare, Inc currently shows a dividend yield of about 2.63% relative to its recent price (as of Sep 29, 2026).
What is the intrinsic value of HCA Healthcare, Inc (H1CA34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HCA Healthcare, Inc it is R$123.09 per share (as of Sep 29, 2026), against a price of R$111.66. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is HCA Healthcare, Inc stock overvalued or undervalued in 2026?
As of Sep 29, 2026, H1CA34 trades below its calculated fair value: price R$111.66, fair value R$123.09, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of H1CA34?
No. The price is what the market pays today (R$111.66); the fair value is what the company's own numbers justify (R$123.09). For HCA Healthcare, Inc the two are R$11.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is HCA Healthcare, Inc worth?
The market values HCA Healthcare, Inc at about R$422B (market capitalisation, as of Sep 29, 2026). Per share that is R$111.66; our models calculate a fair value of R$123.09 per share.
What do the bullish and bearish scenarios say about H1CA34?
Our models span a range for HCA Healthcare, Inc: cautious scenario R$59.07, base R$123.09, optimistic R$190.84 per share (as of Sep 29, 2026, price R$111.66). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is H1CA34 from its 52-week high?
HCA Healthcare, Inc trades at R$111.66, about 22% below its 52-week high of R$142.44 and 21% above the low of R$92.10 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of R$123.09 is for.
Which stocks are comparable to HCA Healthcare, Inc?
From the same area (Healthcare) we also value Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HCA Healthcare, Inc stock attractive at the current price?
The data as of Sep 29, 2026: price R$111.66, calculated fair value R$123.09 (+10%), Quality Score 72/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of H1CA34 calculated?
We run HCA Healthcare, Inc through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$123.09, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. HCA Healthcare, Inc currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on
is it worth investing now.
What is the share price of HCA Healthcare, Inc (H1CA34)?
The closing price on Oct 2, 2026 was R$111.66. Our model-based fair value is R$123.09, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HCA Healthcare, Inc right now?
The model range is unusually wide (R$59.07 to R$190.84). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of HCA Healthcare, Inc
How large is the market capitalisation of HCA Healthcare, Inc (H1CA34)?
The market capitalisation of HCA Healthcare, Inc is R$422B (≈ $80.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of HCA Healthcare, Inc (H1CA34)?
The price-to-earnings ratio of HCA Healthcare, Inc is 14.8. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of HCA Healthcare, Inc (H1CA34)?
The price-to-sales ratio of HCA Healthcare, Inc is 1.33 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HCA Healthcare, Inc (H1CA34)?
Earnings per share at HCA Healthcare, Inc are R$7.52 (price ÷ EPS = P/E 14.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of HCA Healthcare, Inc (H1CA34)?
The dividend yield of HCA Healthcare, Inc is 2.6% (payout 39.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of HCA Healthcare, Inc (H1CA34)?
The net margin of HCA Healthcare, Inc is 9.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HCA Healthcare, Inc (H1CA34)?
The return on equity (ROE) of HCA Healthcare, Inc is 136% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HCA Healthcare, Inc (H1CA34)?
On an EBIT basis the return on assets of HCA Healthcare, Inc is 17.9% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HCA Healthcare, Inc (H1CA34)?
The operating margin of HCA Healthcare, Inc is 15.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HCA Healthcare, Inc (H1CA34)?
Revenue at HCA Healthcare, Inc is growing +4.3% versus a year earlier (3y avg +7.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HCA Healthcare, Inc (H1CA34)?
Earnings per share at HCA Healthcare, Inc are growing +10.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does HCA Healthcare, Inc (H1CA34) generate?
The free cash flow of HCA Healthcare, Inc is $7.7B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does HCA Healthcare, Inc (H1CA34) carry?
The net debt of HCA Healthcare, Inc is $45.5B (fiscal year 2025, ≈ 5.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
